Clinical efficacy and safety of edoxaban for treatment of chronic thromboembolic pulmonary hypertensio
Phase 4
- Conditions
- CTEPH (chronic thromboembolic pulmonary hypertension)
- Registration Number
- JPRN-UMIN000018520
- Lead Sponsor
- Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patient who is scheduled for PEA and/or BPA. 2)Newly initiation of soluble guanylate cyclase stimulator 3)Recent induction of homeoxygen therapy 4)Contraindication for edoxaban 5)High risk patients of bleeding 6)Past history of alveolar hemorrhage 7)cCr<30mL/min 8)Patients who taking more than 2 antiplatelet drugs 9)pregnant/lactating woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method